• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项前瞻性研究,探讨了 STAT1、3、6 在结节性痒疹皮损中的表达及其免疫发病机制和治疗意义。

A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications.

机构信息

Department of Dermatology and STDs, Dr RML Hospital and ABVIMS, New Delhi, India.

Department of Pathology, Dr. RML Hospital and ABVIMS, New Delhi, India.

出版信息

J Cosmet Dermatol. 2022 Sep;21(9):4009-4015. doi: 10.1111/jocd.14709. Epub 2021 Dec 29.

DOI:10.1111/jocd.14709
PMID:34965028
Abstract

BACKGROUND

Prurigo nodularis (PN) is a chronic dermatologic condition manifesting as multiple papulonodular lesions occurring on the background of intense pruritus. PN could be primary or secondary. The exact immune pathogenesis of PN is not yet clear, and multiple pathways are proposed with the JAK-STAT pathway rarely being investigated.

AIMS

In this study, our aim was to assess the role of Th cells in PN by comparing the expression of STAT 1, 3, and 6 in involved and normal skin of primary prurigo nodularis.

METHODS

A total of 49 clinico-histopathologically proven cases of primary prurigo nodularis were included. Two skin biopsies for each patient from lesional and non-lesional skin were stained with STAT 1, 3, and 6, and the nuclear staining pattern in the epidermis was graded as strong, moderate, weak, or none.

RESULTS

Statistically significant expression of STAT 3 and STAT 6 staining was seen in the epidermis of the lesional skin as compared to non-lesional skin.

CONCLUSION

Our study showed a marked dominance of STAT 3 and STAT 6 staining in the epidermis which signifies that the keratinocytes play an important role in PN and suggest that Th2, Th17, and Th22 cytokines mediate the tissue response in PN.

摘要

背景

结节性痒疹(PN)是一种慢性皮肤病,表现为在剧烈瘙痒的背景下出现多个丘疹性结节病变。PN 可为原发性或继发性。PN 的确切免疫发病机制尚不清楚,提出了多种途径,很少研究 JAK-STAT 途径。

目的

本研究旨在通过比较原发性结节性痒疹受累和正常皮肤中 STAT1、3 和 6 的表达,评估 Th 细胞在 PN 中的作用。

方法

共纳入 49 例临床病理证实的原发性结节性痒疹病例。每位患者的皮损和非皮损皮肤均进行了 2 次皮肤活检,分别用 STAT1、3 和 6 染色,并对表皮的核染色模式进行强、中、弱或无分级。

结果

与非皮损皮肤相比,皮损皮肤中 STAT3 和 STAT6 染色的表达具有统计学意义。

结论

我们的研究表明,表皮中 STAT3 和 STAT6 染色明显占优势,这表明角质形成细胞在 PN 中起重要作用,并提示 Th2、Th17 和 Th22 细胞因子介导 PN 中的组织反应。

相似文献

1
A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications.一项前瞻性研究,探讨了 STAT1、3、6 在结节性痒疹皮损中的表达及其免疫发病机制和治疗意义。
J Cosmet Dermatol. 2022 Sep;21(9):4009-4015. doi: 10.1111/jocd.14709. Epub 2021 Dec 29.
2
A Prospective Study Examining the Effect of Selected Topical and Systemic Drugs on Pruritus Grading System Score and STAT 6 Expression in Patients of Prurigo Nodularis.一项前瞻性研究,考察特定局部和全身用药对结节性痒疹患者瘙痒分级系统评分及信号转导和转录激活因子6(STAT 6)表达的影响。
Indian J Dermatol. 2021 Nov-Dec;66(6):638-644. doi: 10.4103/ijd.ijd_341_21.
3
Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis.结节性痒疹表皮中活化的 STAT6 和 STAT3 的核定位。
Br J Dermatol. 2011 Nov;165(5):990-6. doi: 10.1111/j.1365-2133.2011.10498.x. Epub 2011 Sep 29.
4
Prurigo nodularis: new insights into pathogenesis and novel therapeutics.结节性痒疹:发病机制的新见解和新疗法。
Br J Dermatol. 2024 May 17;190(6):798-810. doi: 10.1093/bjd/ljae052.
5
Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.结节性痒疹:发病机制与潜在治疗靶点。
Int J Mol Sci. 2024 May 9;25(10):5164. doi: 10.3390/ijms25105164.
6
Abnormal keratin expression pattern in prurigo nodularis epidermis.结节性痒疹表皮中角蛋白表达模式异常。
Skin Health Dis. 2021 Dec 1;2(1):e75. doi: 10.1002/ski2.75. eCollection 2022 Mar.
7
Prevalence, incidence and treatment patterns of prurigo nodularis in England: a retrospective database analysis.英国结节性痒疹的患病率、发病率和治疗模式:一项回顾性数据库分析。
Br J Dermatol. 2024 Sep 18;191(4):548-555. doi: 10.1093/bjd/ljae207.
8
Aberrant Expression of Histamine-independent Pruritogenic Mediators in Keratinocytes may be Involved in the Pathogenesis of Prurigo Nodularis.角质形成细胞中组胺非依赖性瘙痒介质的异常表达可能与结节性痒疹的发病机制有关。
Acta Derm Venereol. 2019 May 1;99(6):579-586. doi: 10.2340/00015555-3150.
9
Skin Microbiome in Prurigo Nodularis.结节性痒疹的皮肤微生物组。
Int J Mol Sci. 2023 Apr 21;24(8):7675. doi: 10.3390/ijms24087675.
10
A critical evaluation of nemolizumab for prurigo nodularis.对治疗结节性痒疹的 nemolizumab 的评价。
Expert Rev Clin Immunol. 2024 Jun;20(6):577-587. doi: 10.1080/1744666X.2024.2306225. Epub 2024 Jan 19.

引用本文的文献

1
Dupilumab treatment for prurigo nodularis: a retrospective study of 76 patients.度普利尤单抗治疗结节性痒疹:76例患者的回顾性研究
Postepy Dermatol Alergol. 2025 Jun 12;42(3):248-254. doi: 10.5114/ada.2025.152080. eCollection 2025 Jun.
2
Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature.乌帕替尼成功治疗结节性痒疹:一例报告及文献综述
Int Med Case Rep J. 2025 May 28;18:637-644. doi: 10.2147/IMCRJ.S514339. eCollection 2025.
3
Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases.
托法替布成功用于儿童结节性痒疹:4例报告
Indian J Dermatol. 2025 Mar-Apr;70(2):102-104. doi: 10.4103/ijd.ijd_842_24. Epub 2025 Feb 27.
4
Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.结节性痒疹:发病机制与潜在治疗靶点。
Int J Mol Sci. 2024 May 9;25(10):5164. doi: 10.3390/ijms25105164.
5
Molecular mechanisms of pruritus in prurigo nodularis.结节性痒疹瘙痒的分子机制。
Front Immunol. 2023 Nov 23;14:1301817. doi: 10.3389/fimmu.2023.1301817. eCollection 2023.
6
A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib.一例伴有STAT 3和STAT 6表达增强的顽固性结节性痒疹及其对托法替布的显著反应
Indian Dermatol Online J. 2023 May 25;14(4):564-566. doi: 10.4103/idoj.idoj_508_22. eCollection 2023 Jul-Aug.
7
Development of Secondary Prurigo Nodularis in Steroid Modified Tinea Corporis- Documenting a Curious Phenomenon.类固醇治疗的体癣中继发性结节性痒疹的发生——记录一种奇特现象
Indian J Dermatol. 2022 Nov-Dec;67(6):821-822. doi: 10.4103/ijd.ijd_115_22.
8
Itch and Janus Kinase Inhibitors.瘙痒和 Janus 激酶抑制剂。
Acta Derm Venereol. 2023 Feb 15;103:adv00869. doi: 10.2340/actadv.v103.5346.
9
Immunotargets and Therapy for Prurigo Nodularis.结节性痒疹的免疫靶点与治疗
Immunotargets Ther. 2022 Apr 26;11:11-21. doi: 10.2147/ITT.S316602. eCollection 2022.